Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~Exclusion Criteria:~* Use of any medication or anti-oxidant vitamin supplements.~* History of allergic reaction to atazanavir.~* Smoking.~* Previous spontaneous vagal collapse.~* History, signs or symptoms of cardiovascular disease.~* (Family) history of myocardial infarction or stroke under the age of 65 years.~* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.~* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90).~* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50).~* Renal impairment (defined as plasma creatinin \>120 μmol/l).~* Liver enzyme abnormalities or positive hepatitis serology.~* Subjects with a total bilirubin level above 15 μmol/L and a normal direct bilirubin level suggesting Gilbert Syndrome.~* Positive HIV serology or any other obvious disease associated with immune deficiency.~* Febrile illness in the week before the LPS challenge.~* Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
- Atazanavir (Type: ACTIVE_COMPARATOR): Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).